Pixium Vision announced Participation in investor conferences and events in October 2022
Paris, France, October 4, 2022 – 07:00 CET – Pixium Vision SA (Euronext Growth Paris – FR0011950641; Mnemonic: ALPIX), a bioelectronics company developing innovative bionic vision systems to help patients who have lost their sight to live more independently, announces today that management will attend the following investor events in October 2022:
- Biotech AgoraOctober 12th, Paris
Lloyd Diamond, Chief Executive Officer, and Offer Nonhoff, Chief Financial Officer, will host a French-language investor cocktail reception in Paris. Participation is by invitation only.
- HealthTech innovation days, October 13 – 14, Paris
Lloyd Diamond, Chief Executive Officer, and Offer Nonhoff, Chief Financial Officer will be present in person. Registration for the conference is open here.
- European midcap event, October 17th – 18, Paris
Lloyd Diamond, Chief Executive Officer, and Offer Nonhoff, Chief Financial Officer will be present in person. Registration for the conference is open here.
Around Pixium Vision
Pixium Vision creates a world of bionic vision for people who have lost their sight, allowing them to regain visual perception and greater autonomy. Pixium Vision’s bionic vision systems involve a surgical procedure and a rehabilitation period. Prima System’s miniature subretinal photovoltaic wireless implant is in clinical trials for patients who have lost their sight due to external retinal degeneration, initially due to atrophic dry age-related macular degeneration (dry AMD). Pixium Vision works closely with academic and research partners, including some of the most prestigious vision research institutes in the world, such as Stanford University in California, Institut de la Vision in Paris, Moorfields Eye Hospital in London, Institute of Ocular Microsurgery (IMO) in Barcelona , University Hospital in Bonn and UPMC in Pittsburgh, PA. The company is EN ISO 13485…
